Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 8/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 1.00 |
| ▸ | CLK1 | P49759 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 12/20 | 0.77 |
| ▸ | CDK5R1 | Q15078 | 12/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aminopurvalanol SCHEMBL29386084 | 1.00 | CDK1 (1.00) | CDK1CCNB1KDM4ECCNB2ALDH1A1 | |
| Aminopurvalanol SCHEMBL23752328 | 1.00 | CDK1 (1.00) | CDK1CCNB1KDM4ECCNB2ALDH1A1 | |
| Aminopurvalanol SCHEMBL21168739 | 1.00 | CDK1 (1.00) | CDK1CCNB1KDM4ECCNB2ALDH1A1 | |
| Purvalanola SCHEMBL30375366 | 0.87 | CDK5 (1.00) | CDK1CCNB1KDM4ECCNB2ALDH1A1 | |
| Purvalanola SCHEMBL1217069 | 0.87 | CDK5 (1.00) | CDK1CCNB1KDM4ECCNB2ALDH1A1 | |
| Purvalanola SCHEMBL29360281 | 0.87 | CDK5 (1.00) | CDK1CCNB1KDM4ECCNB2ALDH1A1 | |
| Purvalanola SCHEMBL3311119 | 0.87 | CDK5 (1.00) | CDK1CCNB1KDM4ECCNB2ALDH1A1 | |
| SCHEMBL2170687 | 0.86 | CDK1 (0.76) | CDK1CCNB1KDM4ECCNB2ALDH1A1 | |
| SCHEMBL20028216 | 0.84 | CLK1 (0.72) | CDK1CCNB1KDM4ECCNB2ALDH1A1 | |
| SCHEMBL3445809 | 0.83 | CDK1 (0.71) | CDK1CCNB1KDM4ECCNB2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187698-B2 | Crystalline forms of C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. (US) | 2025-01-07 | — | — | US | claimed |
| WO-2024026505-A2 | DISRUPTION OF TELOCYTE ACTIVITY | PATEL AMIT (US) | 2024-02-01 | — | — | WO | claimed |
| US-20230035479-A1 | METHODS AND COMPOSITIONS FOR REDUCING HAIR GREYING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2023-02-02 | — | — | US | claimed |
| US-20220324832-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-13 | — | — | US | claimed |
| CN-107904201-B | Differentiation of human embryonic stem cells into the pancreatic endocrine lineage | 詹森生物科技公司 | 2021-11-16 | — | — | CN | claimed |
| EP-2346988-B1 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS TO THE PANCREATIC ENDOCRINE LINEAGE | JANSSEN BIOTECH INC (US) | 2017-05-31 | — | — | EP | claimed |
| EP-3521419-B1 | METHOD FOR PRODUCING BROWN ADIPOCYTES AND COMPOSITION | KYOTO PREFECTURAL PUBLIC UNIV CORP (JP) | 2026-03-18 | — | — | EP | disclosed |
| US-20260000714-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4653054-A2 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | Biomed Valley Discoveries, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| US-12433920-B2 | C. novyi for the treatment of solid tumors in non-human animals | BIOMED VALLEY DISCOVERIES, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4108248-B1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | BIOMED VALLEY DISCOVERIES INC (US) | 2025-09-17 | — | — | EP | disclosed |
| US-12415986-B2 | Production method for neuron-like cells | KATAOKA CORPORATION (JP) | 2025-09-16 | — | — | US | disclosed |
| US-9234178-B2 | Differentiation of human pluripotent stem cells | JANSSEN BIOTECH, INC. (US) | 2016-01-12 | — | — | US | disclosed |
| EP-2346988-A1 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS TO THE PANCREATIC ENDOCRINE LINEAGE | Centocor Ortho Biotech Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20100311767-A1 | Method for the treatment of amyloidoses | ABBOTT GMBH & CO. KG (DE) | 2010-12-09 | — | — | US | disclosed |
| US-20100311767-A1 | Method for the treatment of amyloidoses | ABBOTT GMBH & CO. KG (DE) | 2010-12-09 | — | — | US | disclosed |
| US-20100112693-A1 | Differentiation of Human Embryonic Stem Cells | CENTOCOR ORTHO BIOTECH, INC. | 2010-05-06 | — | — | US | disclosed |
| WO-2010051223-A1 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS TO THE PANCREATIC ENDOCRINE LINEAGE | CENTOCOR ORTHO BIOTECH INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| WO-2008104386-A2 | METHOD FOR THE TREATMENT OF AMYLOIDOSES | ABBOTT GMBH & CO. KG (DE) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324832-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | CDK1 248/4885CCNB1 75/4885KDM4E 4194/4885 |
| US-12433920-B2 | C. novyi for the treatment of solid tumors in non-human animals | MKI67, HCCS, NCF1 | CDK1 2594/4885CCNB1 1215/4885KDM4E 3726/4885 |
| US-20100311767-A1 | Method for the treatment of amyloidoses | APP, PSEN1, CACNA1G | CDK1 4617/4885CCNB1 4054/4885KDM4E 3926/4885 |
| US-12187698-B2 | Crystalline forms of C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | CDK1 248/4885CCNB1 75/4885KDM4E 4194/4885 |
| US-20260000714-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS | KIT, CPA3, MKI67 | CDK1 639/4885CCNB1 160/4885KDM4E 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.